 Connection
Co-Authors
This is a "connection" page, showing publications co-authored by Jennifer Diamond and David Camidge.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.885 |
|
|
|
-
Diamond JR, Salgia R, Varella-Garcia M, Kanteti R, LoRusso PM, Clark JW, Xu LG, Wilner K, Eckhardt SG, Ching KA, Lira ME, Schoenmakers EF, Christensen JG, Camidge DR. Initial clinical sensitivity and acquired resistance to MET inhibition in MET-mutated papillary renal cell carcinoma. J Clin Oncol. 2013 Jun 01; 31(16):e254-8.
Score: 0.420
-
Alsafar A, Kareem SL, Corr BR, Lieu CH, Wilky B, Davis SL, Camidge DR, Jimeno A, Messersmith WA, Nicklawsky A, Pacheco D, Borrayo EA, McDermott JD, Diamond JR. Increased accrual of diverse patient populations in oncology phase I clinical trials at the University of Colorado Cancer Center. Front Oncol. 2025; 15:1546500.
Score: 0.245
-
Schreiber AR, Kagihara JA, Corr BR, Davis SL, Lieu C, Kim SS, Jimeno A, Camidge DR, Williams J, Heim AM, Martin A, DeMattei JA, Holay N, Triplett TA, Eckhardt SG, Litwiler K, Winkler J, Piscopio AD, Diamond JR. First-in-Human Dose-Escalation Study of the Novel Oral Depsipeptide Class I-Targeting HDAC Inhibitor Bocodepsin (OKI-179) in Patients with Advanced Solid Tumors. Cancers (Basel). 2023 Dec 23; 16(1).
Score: 0.220
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|